{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T02:33:12Z","timestamp":1790044392008,"version":"4.0.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,5,28]],"date-time":"2018-05-28T00:00:00Z","timestamp":1527465600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1038\/s41591-018-0022-x","type":"journal-article","created":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T10:18:30Z","timestamp":1527157110000},"page":"968-977","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":257,"title":["Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition"],"prefix":"10.1038","volume":"24","author":[{"given":"Gabrielle S.","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie Bin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinsen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Schumacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Puschhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"McFarland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin","family":"Dulak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Les","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"O\u2019Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Rendak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-li","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Cecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Hembrough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarit","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Szeto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil K.","family":"Rustgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwok-Kin","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9854-5049","authenticated-orcid":false,"given":"J. Alan","family":"Diehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Graziano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Ruzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaunt","family":"Fereshetian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Mertins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7203-4299","authenticated-orcid":false,"given":"Steven A.","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rameen","family":"Beroukhim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Oki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Catenacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Bass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,28]]},"reference":[{"key":"22_CR1","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nrd4389","volume":"13","author":"AD Cox","year":"2014","unstructured":"Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J. & Der, C. J. Drugging the undruggable RAS: mission possible? Nat. Rev. Drug Discov. 13, 828\u2013851 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"22_CR2","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.ygyno.2013.06.019","volume":"130","author":"JS Ross","year":"2013","unstructured":"Ross, J. S. et al. Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies. Gynecol. Oncol. 130, 554\u2013559 (2013).","journal-title":"Gynecol. Oncol."},{"key":"22_CR3","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/ng.2591","volume":"45","author":"AM Dulak","year":"2013","unstructured":"Dulak, A. M. et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat. Genet. 45, 478\u2013486 (2013).","journal-title":"Nat. Genet."},{"key":"22_CR4","doi-asserted-by":"publisher","first-page":"4383","DOI":"10.1158\/0008-5472.CAN-11-3893","volume":"72","author":"AM Dulak","year":"2012","unstructured":"Dulak, A. M. et al. Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res. 72, 4383\u20134393 (2012).","journal-title":"Cancer Res."},{"key":"22_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0098293","volume":"9","author":"Y Chen","year":"2014","unstructured":"Chen, Y. et al. Identification of druggable cancer driver genes amplified across TCGA datasets. PloS ONE 9, e98293 (2014).","journal-title":"PloS ONE"},{"key":"22_CR6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.canlet.2014.07.021","volume":"353","author":"K Das","year":"2014","unstructured":"Das, K. et al. Mutually exclusive FGFR2, HER2, and KRAS gene amplifications in gastric cancer revealed by multicolour FISH. Cancer Lett. 353, 167\u2013175 (2014).","journal-title":"Cancer Lett."},{"key":"22_CR7","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1038\/bjc.2012.477","volume":"107","author":"E Birkeland","year":"2012","unstructured":"Birkeland, E. et al. KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer. Br. J. Cancer 107, 1997\u20132004 (2012).","journal-title":"Br. J. Cancer"},{"key":"22_CR8","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1128\/MCB.5.10.2836","volume":"5","author":"S Pulciani","year":"1985","unstructured":"Pulciani, S., Santos, E., Long, L. K., Sorrentino, V. & Barbacid, M. ras gene amplification and malignant transformation. Mol. Cell. Biol. 5, 2836\u20132841 (1985).","journal-title":"Mol. Cell. Biol."},{"key":"22_CR9","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1158\/2159-8290.CD-14-1518","volume":"5","author":"LG Ahronian","year":"2015","unstructured":"Ahronian, L. G. et al. Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations. Cancer Discov. 5, 358\u2013367 (2015).","journal-title":"Cancer Discov."},{"key":"22_CR10","doi-asserted-by":"publisher","first-page":"5182","DOI":"10.18632\/oncotarget.3311","volume":"6","author":"M Cargnelutti","year":"2015","unstructured":"Cargnelutti, M. et al. Activation of RAS family members confers resistance to ROS1 targeting drugs. Oncotarget 6, 5182\u20135194 (2015).","journal-title":"Oncotarget"},{"key":"22_CR11","doi-asserted-by":"publisher","first-page":"4504","DOI":"10.1158\/0008-5472.CAN-16-0396","volume":"76","author":"D Oddo","year":"2016","unstructured":"Oddo, D. et al. Molecular landscape of acquired resistance to targeted therapy combinations in BRAF-mutant colorectal cancer. Cancer Res. 76, 4504\u20134515 (2016).","journal-title":"Cancer Res."},{"key":"22_CR12","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1002\/ijc.28106","volume":"133","author":"E Valtorta","year":"2013","unstructured":"Valtorta, E. et al. KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. Int. J. Cancer 133, 1259\u20131265 (2013).","journal-title":"Int. J. Cancer"},{"key":"22_CR13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4161\/sgtp.1.1.12178","volume":"1","author":"AD Cox","year":"2010","unstructured":"Cox, A. D. & Der, C. J. Ras history: The saga continues. Small GTPases 1, 2\u201327 (2010).","journal-title":"Small GTPases"},{"key":"22_CR14","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603\u2013607 (2012).","journal-title":"Nature"},{"key":"22_CR15","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1177\/1758834015571111","volume":"7","author":"E Jokinen","year":"2015","unstructured":"Jokinen, E. & Koivunen, J. P. MEK and PI3K inhibition in solid tumors: rationale and evidence to date. Ther. Adv. Med. Oncol. 7, 170\u2013180 (2015).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"22_CR16","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.celrep.2014.02.045","volume":"7","author":"C Sun","year":"2014","unstructured":"Sun, C. et al. Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. Cell Rep. 7, 86\u201393 (2014).","journal-title":"Cell Rep."},{"key":"22_CR17","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/nrc2960","volume":"10","author":"D Vigil","year":"2010","unstructured":"Vigil, D., Cherfils, J., Rossman, K. L. & Der, C. J. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat. Rev. Cancer 10, 842\u2013857 (2010).","journal-title":"Nat. Rev. Cancer"},{"key":"22_CR18","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/ncomms2173","volume":"3","author":"HH Jeng","year":"2012","unstructured":"Jeng, H. H., Taylor, L. J. & Bar-Sagi, D. Sos-mediated cross-activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis. Nat. Commun. 3, 1168 (2012).","journal-title":"Nat. Commun."},{"key":"22_CR19","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1016\/j.celrep.2015.08.037","volume":"12","author":"A Prahallad","year":"2015","unstructured":"Prahallad, A. et al. PTPN11 is a central node in intrinsic and acquired resistance to targeted cancer drugs. Cell Rep. 12, 1978\u20131985 (2015).","journal-title":"Cell Rep."},{"key":"22_CR20","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/nature18621","volume":"535","author":"YN Chen","year":"2016","unstructured":"Chen, Y. N. et al. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Nature 535, 148\u2013152 (2016).","journal-title":"Nature"},{"key":"22_CR21","doi-asserted-by":"publisher","first-page":"7773","DOI":"10.1021\/acs.jmedchem.6b00680","volume":"59","author":"J Garcia Fortanet","year":"2016","unstructured":"Garcia Fortanet, J. et al. Allosteric inhibition of SHP2: identification of a potent, selective, and orally efficacious phosphatase inhibitor. J. Med. Chem. 59, 7773\u20137782 (2016).","journal-title":"J. Med. Chem."},{"key":"22_CR22","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.cellsig.2007.10.002","volume":"20","author":"M Dance","year":"2008","unstructured":"Dance, M., Montagner, A., Salles, J. P., Yart, A. & Raynal, P. The molecular functions of Shp2 in the Ras\/Mitogen-activated protein kinase (ERK1\/2) pathway. Cell. Signal. 20, 453\u2013459 (2008).","journal-title":"Cell. Signal."},{"key":"22_CR23","doi-asserted-by":"publisher","first-page":"8859","DOI":"10.1038\/ncomms9859","volume":"6","author":"S Bunda","year":"2015","unstructured":"Bunda, S. et al. Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis. Nature Commun. 6, 8859 (2015).","journal-title":"Nature Commun."},{"key":"22_CR24","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S1097-2765(04)00050-4","volume":"13","author":"SQ Zhang","year":"2004","unstructured":"Zhang, S. Q. et al. Shp2 regulates SRC family kinase activity and Ras\/Erk activation by controlling Csk recruitment. Mol. Cell 13, 341\u2013355 (2004).","journal-title":"Mol. Cell"},{"key":"22_CR25","doi-asserted-by":"publisher","first-page":"7875","DOI":"10.1128\/MCB.23.21.7875-7886.2003","volume":"23","author":"YM Agazie","year":"2003","unstructured":"Agazie, Y. M. & Hayman, M. J. Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling. Mol. Cell. Biol. 23, 7875\u20137886 (2003).","journal-title":"Mol. Cell. Biol."},{"key":"22_CR26","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1016\/j.cub.2006.09.033","volume":"16","author":"S Boykevisch","year":"2006","unstructured":"Boykevisch, S. et al. Regulation of ras signaling dynamics by Sos-mediated positive feedback. Curr. Biol. 16, 2173\u20132179 (2006).","journal-title":"Curr. Biol."},{"key":"22_CR27","doi-asserted-by":"publisher","first-page":"41677","DOI":"10.1074\/jbc.M306461200","volume":"278","author":"T Araki","year":"2003","unstructured":"Araki, T., Nawa, H. & Neel, B. G. Tyrosyl phosphorylation of Shp2 is required for normal ERK activation in response to some, but not all, growth factors. J. Biol. Chem. 278, 41677\u201341684 (2003).","journal-title":"J. Biol. Chem."},{"key":"22_CR28","first-page":"1327","volume":"11","author":"L Buday","year":"1995","unstructured":"Buday, L., Warne, P. H. & Downward, J. Downregulation of the Ras activation pathway by MAP kinase phosphorylation of Sos. Oncogene 11, 1327\u20131331 (1995).","journal-title":"Oncogene"},{"key":"22_CR29","doi-asserted-by":"publisher","first-page":"33540","DOI":"10.1074\/jbc.M110.135517","volume":"285","author":"Y Kamioka","year":"2010","unstructured":"Kamioka, Y., Yasuda, S., Fujita, Y., Aoki, K. & Matsuda, M. Multiple decisive phosphorylation sites for the negative feedback regulation of SOS1 via ERK. J. Biol. Chem. 285, 33540\u201333548 (2010).","journal-title":"J. Biol. Chem."},{"key":"22_CR30","doi-asserted-by":"publisher","first-page":"5871","DOI":"10.1074\/jbc.271.10.5871","volume":"271","author":"E Porfiri","year":"1996","unstructured":"Porfiri, E. & McCormick, F. Regulation of epidermal growth factor receptor signaling by phosphorylation of the ras exchange factor hSOS1. J. Biol. Chem. 271, 5871\u20135877 (1996).","journal-title":"J. Biol. Chem."},{"key":"22_CR31","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/nature18600","volume":"534","author":"E Manchado","year":"2016","unstructured":"Manchado, E. et al. A combinatorial strategy for treating KRAS-mutant lung cancer. Nature 534, 647\u2013651 (2016).","journal-title":"Nature"},{"key":"22_CR32","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.ccr.2014.03.011","volume":"25","author":"P Lito","year":"2014","unstructured":"Lito, P. et al. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell 25, 697\u2013710 (2014).","journal-title":"Cancer Cell"},{"key":"22_CR33","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.cell.2017.01.020","volume":"168","author":"MR Burgess","year":"2017","unstructured":"Burgess, M. R. et al. KRAS allelic imbalance enhances fitness and modulates MAP kinase dependence in cancer. Cell 168, 817\u2013829 (2017).","journal-title":"Cell"},{"key":"22_CR34","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1093\/neuonc\/nox044","volume":"19","author":"RS McNeill","year":"2017","unstructured":"McNeill, R. S. et al. Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma. Neuro-oncol. 19, 1469\u20131480 (2017).","journal-title":"Neuro-oncol."},{"key":"22_CR35","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1158\/2159-8290.CD-16-0653","volume":"7","author":"JS Zawistowski","year":"2017","unstructured":"Zawistowski, J. S. et al. Enhancer remodeling during adaptive bypass to MEK inhibition is attenuated by pharmacologic targeting of the P-TEFb complex. Cancer Discov. 7, 302\u2013321 (2017).","journal-title":"Cancer Discov."},{"key":"22_CR36","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1158\/1541-7786.MCR-15-0203","volume":"13","author":"JC Hunter","year":"2015","unstructured":"Hunter, J. C. et al. Biochemical and structural analysis of common cancer-associated KRAS mutations. Mol. Cancer Res. 13, 1325\u20131335 (2015).","journal-title":"Mol. Cancer Res."},{"key":"22_CR37","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1126\/science.aad6204","volume":"351","author":"P Lito","year":"2016","unstructured":"Lito, P., Solomon, M., Li, L. S., Hansen, R. & Rosen, N. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science 351, 604\u2013608 (2016).","journal-title":"Science"},{"key":"22_CR38","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1021\/jm501660t","volume":"58","author":"JJ Winter","year":"2015","unstructured":"Winter, J. J. et al. Small molecule binding sites on the Ras:SOS complex can be exploited for inhibition of Ras activation. J. Med. Chem. 58, 2265\u20132274 (2015).","journal-title":"J. Med. Chem."},{"key":"22_CR39","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1016\/j.chembiol.2014.09.018","volume":"21","author":"CR Evelyn","year":"2014","unstructured":"Evelyn, C. R. et al. Rational design of small molecule inhibitors targeting the Ras GEF, SOS1. Chem. Biol. 21, 1618\u20131628 (2014).","journal-title":"Chem. Biol."},{"key":"22_CR40","doi-asserted-by":"publisher","first-page":"5766","DOI":"10.1016\/j.bmcl.2012.07.082","volume":"22","author":"W Wang","year":"2012","unstructured":"Wang, W., Fang, G. & Rudolph, J. Ras inhibition via direct Ras binding\u2014is there a path forward? Bioorg. Med. Chem. Lett. 22, 5766\u20135776 (2012).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"22_CR41","doi-asserted-by":"publisher","first-page":"19748","DOI":"10.18632\/oncotarget.7782","volume":"7","author":"R Tokunaga","year":"2016","unstructured":"Tokunaga, R. et al. Fibroblast growth factor receptor 2 expression, but not its genetic amplification, is associated with tumor growth and worse survival in esophagogastric junction adenocarcinoma. Oncotarget 7, 19748\u201319761 (2016).","journal-title":"Oncotarget"},{"key":"22_CR42","doi-asserted-by":"publisher","unstructured":"Maron, S. B. et al. Targeted therapies for targeted populations: anti-EGFR treatment for EGFR amplified gastroesophageal adenocarcinoma. Cancer Discov. \n                    https:\/\/doi.org\/10.1158\/2159-8290.CD-17-1260\n                    \n                   (2018).","DOI":"10.1158\/2159-8290.CD-17-1260"},{"key":"22_CR43","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"The Cancer Genome Atlas Research Network.","year":"2014","unstructured":"The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202\u2013209 (2014).","journal-title":"Nature"},{"key":"22_CR44","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1158\/2159-8290.CD-11-0175","volume":"1","author":"DV Catenacci","year":"2011","unstructured":"Catenacci, D. V. et al. Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discov. 1, 573\u2013579 (2011).","journal-title":"Cancer Discov."},{"key":"22_CR45","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1038\/nprot.2013.153","volume":"8","author":"H Miyoshi","year":"2013","unstructured":"Miyoshi, H. & Stappenbeck, T. S. In vitro expansion and genetic modification of gastrointestinal stem cells in spheroid culture. Nat. Protoc. 8, 2471\u20132482 (2013).","journal-title":"Nat. Protoc."},{"key":"22_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0100586","volume":"9","author":"DV Catenacci","year":"2014","unstructured":"Catenacci, D. V. et al. Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue. PloS ONE 9, e100586 (2014).","journal-title":"PloS ONE"},{"key":"22_CR47","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.jmoldx.2013.03.002","volume":"15","author":"T Hembrough","year":"2013","unstructured":"Hembrough, T. et al. Application of selected reaction monitoring for multiplex quantification of clinically validated biomarkers in formalin-fixed, paraffin-embedded tumor tissue. J. Mol. Diagn. 15, 454\u2013465 (2013).","journal-title":"J. Mol. Diagn."}],"updated-by":[{"DOI":"10.1038\/s41591-018-0168-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,8,9]],"date-time":"2018-08-09T00:00:00Z","timestamp":1533772800000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41591-018-0022-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41591-018-0022-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41591-018-0022-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:55:56Z","timestamp":1684605356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-018-0022-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,28]]},"references-count":47,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["22"],"URL":"https:\/\/doi.org\/10.1038\/s41591-018-0022-x","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,28]]},"assertion":[{"value":"12 October 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2018","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the Supplementary Information originally published with this article, a lane was missing in the \u03b2-actin blot in Supplementary Fig. 2. The lane has been added. The error has been corrected in the Supplementary Information associated with this article.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.S.W. is now an employee of Novartis Institutes for Biomedical Research, Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}